New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.

Abstract

On July 25, the US Food and Drug Administration (FDA) approved alirocumab (Praluent), the first in a new class, the proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors. Approval of a second medication in the class is expected shortly. The injected medications are used to treat patients with hyperlipidemia, and early results suggest these drugs… (More)
DOI: 10.1001/jama.2015.10017

Topics

  • Blog articles referencing this paper

  • Presentations referencing similar topics